Condition: Pediatric · Symptomatic Obstructive Hypertrophic Cardiomyopathy · Sponsor: Cytokinetics
The purpose of this study is to evaluate the efficacy, safety and PK of aficamten in a pediatric population with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
This description comes directly from the study's public registry record.
Cytokinetics MD · 6506242929 · medicalaffairs@cytokinetics.com
Always discuss trial participation with your own doctor first.
| Phoenix Children's Hospital | Phoenix, Arizona, United States | Recruiting |
| Children's Hospital Los Angeles | Los Angeles, California, United States | Recruiting |
| University of California, Los Angeles (UCLA) | Los Angeles, California, United States | Recruiting |
| UCSF Benioff Children's Hospital | San Francisco, California, United States | Not Yet Recruiting |
| Children's Hospital Colorado | Aurora, Colorado, United States | Recruiting |
| Children's National Hospital | Washington D.C., District of Columbia, United States | Recruiting |
| Nicklaus Children's Hospital | Miami, Florida, United States | Recruiting |
| Ann & Robert H. Lurie Children's Hospital | Chicago, Illinois, United States | Recruiting |
| University of Iowa | Iowa City, Iowa, United States | Withdrawn |
| Children's Hospital New Orleans | New Orleans, Louisiana, United States | Recruiting |
| University of Michigan | Ann Arbor, Michigan, United States | Recruiting |
| Children's Hospital of Michigan | Detroit, Michigan, United States | Recruiting |
+ 26 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06412666